CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 269 participants.

Also called NCT06886113

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 269 participants (planned count) (from the registry)
Sponsor
Shenzhen Core Medical Technology CO.,LTD. (from the registry)
Registry
  • NCT NCT06886113
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06886113. Randomized; no masking; primary purpose treatment. Start 2025-10-01 (anticipated); primary completion 2026-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
Acronym
Corvad AMICS
Condition
Cardiogenic Shock
Intervention (Device)
Conventional circulatory support
Intervention (Device)
CorVad
Lead sponsor
Shenzhen Core Medical Technology CO.,LTD. (class: industry)

Record details

Record id
cardio:ct-nct06886113
Content hash
b267001ede6a9c3c64422b20a2629998506f6393fa28b0df5093d28de4d24eff